

Cover Story
By Matthew Bin Han Ong
Tecentriq, Genentech's PD-L1 checkpoint inhibitor, is the first immunotherapy agent to report positive outcomes in breast cancer in a phase III trial—providing proof of principle that these drugs are active in treatment of triple-negative breast cancer.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care - David Liu awarded 2025 Breakthrough Prize in Life Sciences
- Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park